Avidity Biosciences Inc RNA

NAS: RNA | ISIN: US05370A1088   30/04/2025
32,65 USD (+1,52%)
(+1,52%)   30/04/2025

21 april 2025 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 april 2025 · Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 · Persbericht

1 april 2025 · Avidity Biosciences to Participate in Upcoming Investor Conference · Persbericht

31 maart 2025 · Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy · Persbericht

21 maart 2025 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

17 maart 2025 · Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial · Persbericht

12 maart 2025 · Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference · Persbericht

5 september 2024 · Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month · Persbericht

28 augustus 2024 · Avidity Biosciences to Participate in Upcoming Investor Conferences · Persbericht

21 augustus 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

19 augustus 2024 · Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

15 augustus 2024 · Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock · Persbericht

13 augustus 2024 · Avidity Biosciences Announces Proposed Public Offering of Common Stock · Persbericht

9 augustus 2024 · Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights · Persbericht

9 augustus 2024 · Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial · Persbericht

5 augustus 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 augustus 2024 · Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer · Persbericht

22 juli 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

21 juni 2024 · Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 juni 2024 · Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day · Persbericht

Mijn selecties